Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors
摘要:
HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.
A sequential carbo-formylation cascade has been developed, involving a free-radical carbo-oximation process, followed by the hydrolysis of the oxime ether. For this purpose, we designed a new SEM O-protected sulfonyl oxime, which enable both rapid radical addition and hydrolysis under mild conditions. The resulting aldehyde-esters were then engaged in various nucleophilic cascades, such as Sakurai
The present invention is directed to compounds of formula (I),
and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.